AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Sensation Seeking and TMS Response in TRD

Recruitingn/aAges 18 Years - anyAllTechnical University of Munich
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

his real-world observational study examines whether sensation-seeking personality traits influence the clinical response to transcranial magnetic stimulation (TMS) in patients with treatment-resistant depression (TRD). Participants will complete a validated sensation seeking scale prior to TMS treatment, and depressive symptoms will be assessed using standardized clinical scales during and after the TMS course.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Adults (โ‰ฅ18 years). * Diagnosis according to ICD-10: recurrent depressive disorder, severe depressive disorder, schizoaffective disorder (depressive episode) or bipolar affective disorder (depressive episode). * Treatment-Resistant Depression (TRD): inadequate response to โ‰ฅ2 adequate antidepressant trials in the current episode (per clinician judgment or ATHF if available). * Baseline assessments available: MADRS within โ‰ค7 days before first TMS session and baseline Sensation Seeking Scale (SSS) prior to or at treatment initiation. * Capacity to provide informed consent and ability to complete study questionnaires in the site language. Exclusion Criteria: * Contraindications to TMS (per device labeling/clinical standards): any ferromagnetic or electronic intracranial/cranial implants, cochlear implant, deep brain stimulator, medication pump near coil, skull defect, or other conditions deemed unsafe by the treating clinician. * History of seizure/epilepsy (except single, clearly provoked event), current epileptiform disorder, or significant neurological disease lowering seizure threshold (e.g., recent stroke, brain tumor, active TBI with persistent sequelae, active CNS infection). * Moderate-to-severe substance use disorder within the past 3 months (excluding nicotine/caffeine), per clinician assessment. * Imminent suicide risk requiring a higher level of care (e.g., active plan/intent) at screening. * Concurrent acute ECT or investigational device/drug during the TMS acute course (participation allowed if such treatments are not initiated during the observation window). * Any condition that, in the judgment of the treating clinician or PI, would preclude safe TMS delivery or reliable outcome measurement (e.g., severe cognitive impairment preventing valid MADRS/SSS completion).
๐Ÿ’Š

What it tests

  • Transcranial Magnetic Stimulation (TMS)
๐Ÿ“

Where

1 site
Technical University of Munich, TUM School of Medicine and Health, Department of Psychiatry and Psychotherapy,
Mรผnchen, Germany
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy